生物技术公司Immunic和BioHarvest将在2026年3月的投资者会议上发表报告,展示管道更新和战略增长. Biotech firms Immunic and BioHarvest to present at investor conferences in March 2026, showcasing pipeline updates and strategic growth.

生物技术公司 Immunic 开发神经和胃肠道疾病的口服疗法,将于3月11日在迈阿密举行的 Jefferies 全球医疗保健会议和3月18日在 J.P.摩根医疗保健会议上发表讲话,旨在分享其临床管道和战略方向的最新信息. Immunic, a biotech company developing oral therapies for neurological and gastrointestinal diseases, will present at the Jefferies Global Healthcare Conference in Miami on March 11 and the J.P. Morgan Healthcare Conference on March 18, aiming to share updates on its clinical pipeline and strategic direction. 该公司的参与包括执行陈述和投资者会议。 The company’s participation includes executive presentations and investor meetings. 同时,BioHarvest Sciences将出席3月22日至24日在Dana Point举行的第38届年度Roth会议,首席执行官Ilan Sobel将在会上与机构投资者会晤。 Meanwhile, BioHarvest Sciences will attend the 38th Annual Roth Conference in Dana Point from March 22 to 24, where CEO Ilan Sobel will meet with institutional investors. 2025年,在 " 问题4 " 成功开展一轮融资之后,BioHarvest着重指出了85 000多个直接消费者和新的制造业伙伴关系。 BioHarvest highlighted over 85,000 direct consumers and new manufacturing partnerships following a successful financing round in Q4 2025. 这两场活动都由积极主动的金融新闻提供商主办,该提供商因促销这些公司而获得报酬。 Both events are hosted by Proactive, a financial news provider that receives compensation for promoting these companies.